Evidence map›Paper›PMID 40301336›Full record

ArticleNature communications2025

Network-based clustering unveils interconnected landscapes of genomic and clinical features across myeloid malignancies.

Fritz Bayer, Marco Roncador, Giusi Moffa, Kiyomi Morita, Koichi Takahashi, Niko Beerenwinkel, Jack Kuipers

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fritz BayerDepartment of Biosystems Science and Engineering, ETH Zurich, Schanzenstrasse 44, 4056, Basel, Switzerland.
Marco RoncadorDepartment of Biosystems Science and Engineering, ETH Zurich, Schanzenstrasse 44, 4056, Basel, Switzerland.
Giusi MoffaDepartment of Mathematics and Computer Science, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-2739-0454
Kiyomi MoritaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8027-9659
Niko BeerenwinkelDepartment of Biosystems Science and Engineering, ETH Zurich, Schanzenstrasse 44, 4056, Basel, Switzerland.ORCID http://orcid.org/0000-0002-0573-6119
Jack KuipersDepartment of Biosystems Science and Engineering, ETH Zurich, Schanzenstrasse 44, 4056, Basel, Switzerland. jack.kuipers@bsse.ethz.ch.ORCID http://orcid.org/0000-0001-5357-2705

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid malignancies exhibit considerable heterogeneity with overlapping clinical and genetic features among subtypes. We present a data-driven approach that integrates mutational features and clinical covariates at diagnosis within networks of their probabilistic relationships, enabling the discovery of patient subgroups. A key strength is its ability to include presumed causal directions in the edges linking clinical and mutational features, and account for them aptly in the clustering. In a cohort of 1323 patients, we identify subgroups that outperform established risk classifications in prognostic accuracy. Our approach generalises well to unseen cohorts with classification based on our subgroups similarly offering advantages in predicting prognosis. Our findings suggest that mutational patterns are often shared across myeloid malignancies, with distinct subtypes potentially representing evolutionary stages en route to leukemia. With pancancer TCGA data, we observe that our modelling framework extends naturally to other cancer types while still offering improvements in subgroup discovery.

Indexed as

Myeloproliferative DisordersCluster AnalysisCohort StudiesFemaleGenomicsHumansMaleMutationPrognosis

Identifiers

PMID40301336
PMCPMC12041249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.